TRAIN Akademie - Key Note Lecture
Öffentliche Vorlesung im Rahmen des Weiterbildungsprogramms „Translationale Forschung & Medizin: Von der Idee zum Produkt“ der TRAIN-Akademie:
Sprecher: Lothar Germeroth, Ph.D. | Juno Therapeutics GmbH
"CAR-T-Cells for the Treatment of Cancer"
Wann: Donnerstag, 10.08.2017, 16:30 Uhr
Wo: TWINCORE | Seminarraum 002
Lothar Germeroth is Managing Director, of the Juno Therapeutics GmbH, SVP of Juno Therapeutics, Inc., and joined Juno through the acquisition of Stage Cell Therapeutics in May 2015. Dr. Germeroth has over 25 years of experience in the field of biotechnology. Most recently, he served as the CEO at IBA GmbH and the COO at Stage Cell Therapeutics GmbH, and served eight years as CEO in three different German Biotech companies (Jerini BioTools GmbH, Chemotopix GmbH, Cytos Proteome Therapeutics GmbH) and as Chief Business Officer at Cytos Biotechnology AG in Switzerland. Dr. Germeroth studied chemistry in Frankfurt/Main and obtained his PhD in Biochemistry in the department of Nobel Prize Laureate Professor Hartmut Michel at the Max-Planck Institute of Biophysics in Frankfurt.
- TRAIN_KL_Germeroth_final.pdf130 Ki